A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal ...

bjmu.edu.cn Objective Familial adenomatous polyposis (FAP) is characterised by the development of hundreds to thousands of adenomas at different evolutionary stages in the colon and rectum that will ...

Correspondence to Dr Yin Cao, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; yin.cao{at}wustl.edu and Dr Xuehong Zhang, Brigham and Women’s ...

Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...

1 Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, WA, United States 2 UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, ...

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...